Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology

Dubey, Abhishek; Dahiya, Surbhi; Rouse, Barry T.; Sehrawat, Sharvan

doi:10.3389/fimmu.2020.581076

Cited by 6 publications

(5 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, antibody-based pharmaceuticals like Casirivimab and Imdevimab are already used to treat COVID-19 infection ( Sun and Ho 2020 ). Therefore, besides application in virus diagnostics, nanobodies directed against SARS-CoV2 could potentially even become novel pharmaceutical targets for therapeutic approaches ( Dubey et al, 2020 ). The unique system of unconventional secretion in U. maydis now offers new possibilities for nanobody production without the risk of undesired modifications by N -glycosylation ( Stock et al, 2012 ).…”

Section: Discussionmentioning

confidence: 99%

A Novel Potent Carrier for Unconventional Protein Export in Ustilago maydis

Philipp

Hussnaetter

Reindl

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Recombinant proteins are ubiquitously applied in fields like research, pharma, diagnostics or the chemical industry. To provide the full range of useful proteins, novel expression hosts need to be established for proteins that are not sufficiently produced by the standard platform organisms. Unconventional secretion in the fungal model Ustilago maydis is an attractive novel option for export of heterologous proteins without N-glycosylation using chitinase Cts1 as a carrier. Recently, a novel factor essential for unconventional Cts1 secretion termed Jps1 was identified. Here, we show that Jps1 is unconventionally secreted using a fusion to bacterial β-glucuronidase as an established reporter. Interestingly, the experiment also demonstrates that the protein functions as an alternative carrier for heterologous proteins, showing about 2-fold higher reporter activity than the Cts1 fusion in the supernatant. In addition, Jps1-mediated secretion even allowed for efficient export of functional firefly luciferase as a novel secretion target which could not be achieved with Cts1. As an application for a relevant pharmaceutical target, export of functional bi-specific synthetic nanobodies directed against the SARS-CoV2 spike protein was demonstrated. The establishment of an alternative efficient carrier thus constitutes an excellent expansion of the existing secretion platform.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel Potent Carrier for Unconventional Protein Export in Ustilago maydis

Philipp

Hussnaetter

Reindl

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…While additional SARS-CoV-2 mutations will continue to arise, nanobodies are promising strategies for preventing COVID-19 mortality if vaccinations are damaged56. This potential alternative of using camelid nanobodies promises to be a revolutionary therapy in searching for new drugs against Coronavirus disease (COVID-19) 10,36,57,58 .…”

Section: Potential Biomedical Application Of Camelids Immunoglobulinsmentioning

confidence: 99%

Study review of camelid and shark antibodies for biomedical and biotechnological applications

Alcivar

Maily

2021

View full text Add to dashboard Cite

The antibodies of camelids and sharks are about one–half of the conventional ones while regular antibodies have four protein chains: two light and two heavy, these small antibodies studied have just two heavy chains; they lack a light chain. In recent years, nanobodies have been the focus of attention because they can recognize epitopes that are usually not antigenic (hidden) for conventional antibodies. On the clinical side, researchers are testing nanobodies (Nbs) in the fight against diseases and disease diagnosis. Nanobodies also are attractive because they can prevent protein aggregation and clear the already existing aggregates. Furthermore, new treatments using these Nbs can neutralize the severe acute respiratory syndrome coronavirus (SARS-CoV-2) for preventing COVID-19. In this review, we sum up recent findings of the proposed nanobodies for their potential application.

show abstract

“…These include vaccines against Feline Leukemia Virus infection and the cat enteric coronavirus (FeCoV) that occasionally mutates and then causes a lethal peritonitis (FIP) following a mutation in the spike glycoprotein [ 97 ]. Past attempts at vaccinating against FIP have been unsuccessful, with some vaccine formulations making animals even more likely to develop FIP [ 98 , 99 ]. Given the success of mRNA vaccines against the human coronavirus SARS-CoV-2, a strong case can be made to explore the mRNA approach against FIP.…”

Section: Introductionmentioning

confidence: 99%